AIM
TAK icon

Advantage Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Advantage Investment Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$93K Sell
5,428
-350
-6% -$6.05K 0.07% 244
2019
Q2 		$102K Sell
5,778
-153
-3% -$2.78K 0.08% 234
2019
Q1 		$121K Buy
+5,931
New +$119K 0.1% 211

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Advantage Investment Management's TAK Position: Q3 2019 in Review

Advantage Investment Management reduced its Takeda Pharmaceutical (TAK) stake by 6.1% in Q3 2019, selling an estimated $6.05K and leaving 5,428 shares worth $93K. The position accounts for 0.07% of the portfolio, ranked #244.

Advantage Investment Management first reported a position in TAK in Q1 2019 and has held it in 3 quarters since. The position peaked at $121K in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • Advantage Investment Management held 5,428 shares of Takeda Pharmaceutical worth $93K as of Q3 2019.
  • Advantage Investment Management sold 350 Takeda Pharmaceutical shares in Q3 2019, an estimated $6.05K.
  • Takeda Pharmaceutical made up 0.07% of Advantage Investment Management's portfolio in Q3 2019, its #244 holding.
  • Advantage Investment Management first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 3 quarters since.
  • Advantage Investment Management's Takeda Pharmaceutical position peaked at $121K in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.